Press Releases

Press Releases

  1. First patient in Malaysia receives TheraSphere™ radioembolisation therapy

  2. BTG and Mirada Medical announce CE Mark Certification for Simplicit90Y dosimetry software in Europe

  3. BTG plc: close period update

  4. BTG: settlement of US government investigation into LC Bead®

  5. BTG Launches βETA™ Radiation Safety Programme, to Reduce the Risk of Radiation Exposure for Healthcare Professionals and Patients

  6. BTG receives Health Canada approval for DC Bead LUMI™

  7. CMS Grants Vistogard® New Technology Add-on Payment Status Effective 1 October 2016

  8. BTG plc: Appointment of Non-executive Director

  9. BTG plc: Annual General Meeting

  10. Varithena® Earns FDA Approval for 30 Day Post-Activation Shelf Life

  11. BTG completes the acquisition of Galil Medical

  12. BTG Joins Global Liver Institute Partnership Network to Transform Care for Liver Cancer Patients

  13. New study highlights potential cost savings when using yttrium-90 glass microspheres for treatment of hepatocellular carcinoma

  14. BTG plc: Final Results 2016

  15. BTG plc acquires Galil Medical, a leader in cryoablation

  16. BTG plc: Close Period Update

  17. BTG to Initiate Multi-Centre TARGET Study Evaluating Dosimetry for 90Y Radioembolisation Therapy in Patients With Hepatocellular Carcinoma

  18. BTG announces US launch of LC Bead LUMI™, ground-breaking radiopaque embolic bead

  19. BTG International Canada Expands Operations To Directly Sell Interventional Oncology Products

  20. New Data from Largest Prospective Study on CroFab® for Treatment of Copperhead Snake Envenomation

  21. First Patient Treated With LC Bead LUMI™ Radiopaque Embolic Bead Supported by Philips Live Image Guidance

  22. First Patients in South Korea Receive TheraSphere® Radioembolisation Treatment

  23. BTG Announces Presentation of New Vistogard® (uridine triacetate) Data at American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI)